We are live on ! Find out more
MTNB icon

Matinas BioPharma
MTNB

35 hedge funds and large institutions have $8.24M invested in Matinas BioPharma in 2018 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 6 increasing their positions, 2 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 2

40% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 10

25% more capital invested

Capital invested by funds: $6.6M → $8.24M (+$1.64M)

13% more funds holding

Funds holding: 31 → 35 (+4)

0.09% more ownership

Funds ownership: 0.15% → 0.25% (+0.09%)

Holders
35
Holders Change
+4
Holders Change %
+12.9%
% of All Funds
0.78%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
14
Increased
6
Reduced
2
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BC
Boxer Capital
California
+$4.43M
2
IA
IFP Advisors
Florida
+$960K
3
AGM
Alpine Global Management
New York
+$324K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$179K
5
BlackRock
BlackRock
New York
+$136K

Top Sellers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
-$261K
2
ECM
Element Capital Management
New York
-$231K
3
Creative Planning
Creative Planning
Kansas
-$187K
4
RJFSA
Raymond James Financial Services Advisors
Florida
-$178K
5
KJHP
K.J. Harrison & Partners
Ontario, Canada
-$150K
Name Holding Trade Value Shares
Change 		Change in
Stake
USAA
26
United Services Automobile Association
Texas
$7K – – –
Commonwealth Equity Services
27
Commonwealth Equity Services
Massachusetts
$6K – – –
FC
28
Fore Capital
New York
$6K – – –
CHP
29
Cable Hill Partners
Oregon
$6K +$7.85K +200 New
CFS
30
CRA Financial Services
New Jersey
$6K +$7.85K +200 New
BNP Paribas Financial Markets
31
BNP Paribas Financial Markets
France
$2.85K – – –
Morgan Stanley
32
Morgan Stanley
New York
$2K – – –
CAL
33
Capital Analysts LLC
Pennsylvania
$1K +$981 +25 New
HFM
34
Hartford Financial Management
Connecticut
$1K +$1.96K +50 New
Goldman Sachs
35
Goldman Sachs
New York
– -$261K -5,667 Closed
ECM
36
Element Capital Management
New York
– -$231K -5,019 Closed
Creative Planning
37
Creative Planning
Kansas
– -$187K -4,065 Closed
KJHP
38
K.J. Harrison & Partners
Ontario, Canada
– -$150K -3,269 Closed
Renaissance Technologies
39
Renaissance Technologies
New York
– -$124K -2,698 Closed
BCM
40
BlueCrest Capital Management
Jersey
– -$72K -1,557 Closed
Millennium Management
41
Millennium Management
New York
– -$69K -1,496 Closed
BFM
42
Boothbay Fund Management
New York
– -$39K -850 Closed
Deutsche Bank
43
Deutsche Bank
Germany
– -$10K -215 Closed
Bank of America
44
Bank of America
North Carolina
– -$1K -20 Closed
1
2

MTNB Hedge Fund Activity: Q4 2018 in Review

35 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q4 2018, worth a combined $8.24M — up 25% from $6.6M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new MTNB positions and 10 closed out — a net gain of 4 holders — while 6 added to existing stakes and 2 trimmed.

The largest buyer was Boxer Capital, opening a new position worth an estimated $4.43M. The largest seller was Goldman Sachs, exiting entirely with an estimated $261K sold.

  • 35 institutional investors held Matinas BioPharma (MTNB) as of Q4 2018, up from 31 in Q3 2018.
  • Funds reported $8.24M of Matinas BioPharma stock for Q4 2018, up 25% quarter-over-quarter.
  • 14 funds opened new Matinas BioPharma positions in Q4 2018 and 10 closed out, a net change of +4 holders.
  • The largest Matinas BioPharma buyer in Q4 2018 was Boxer Capital, an estimated $4.43M added.
  • The largest Matinas BioPharma seller in Q4 2018 was Goldman Sachs, an estimated $261K sold.

Based on aggregated 13F filings for Q4 2018.